PortalPublikationenElevated pretreatment serum concentration of YKL-40-An indep...

Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer.

Standard

Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. / Thoem, Ina; Andritzky, Birte; Schuch, Gunter; Burkholder, Iris; Edler, Lutz; Johansen, Julia S; Bokemeyer, Carsten; Schumacher, Udo; Laack, Heinz-Eckart.

in: CANCER-AM CANCER SOC, Jahrgang 116, Nr. 17, 17, 2010, S. 4114-4121.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Thoem, I, Andritzky, B, Schuch, G, Burkholder, I, Edler, L, Johansen, JS, Bokemeyer, C, Schumacher, U & Laack, H-E 2010, 'Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer.', CANCER-AM CANCER SOC, Jg. 116, Nr. 17, 17, S. 4114-4121. <http://www.ncbi.nlm.nih.gov/pubmed/20564116?dopt=Citation>

APA

Thoem, I., Andritzky, B., Schuch, G., Burkholder, I., Edler, L., Johansen, J. S., Bokemeyer, C., Schumacher, U., & Laack, H-E. (2010). Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. CANCER-AM CANCER SOC, 116(17), 4114-4121. [17]. http://www.ncbi.nlm.nih.gov/pubmed/20564116?dopt=Citation

Vancouver

Thoem I, Andritzky B, Schuch G, Burkholder I, Edler L, Johansen JS et al. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. CANCER-AM CANCER SOC. 2010;116(17):4114-4121. 17.

Bibtex

@article{c63d6273c4a24062b1445e16c03f5e94,
title = "Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer.",
abstract = "The glycoprotein YKL-40 is synthesized both by cancer cells and by tumor-associated macrophages and plays a functional role in tumor progression. Consequently, high serum YKL-40 levels have been associated with a poor prognosis in patients with several cancer types. However, the role of YKL-40 has not been established in nonsmall cell lung cancer (NSCLC).",
keywords = "Adult, Humans, Male, Aged, Female, Middle Aged, Tumor Markers, Biological blood, Prognosis, Disease-Free Survival, Neoplasm Metastasis, Carcinoma, Non-Small-Cell Lung blood, Glycoproteins blood, Lectins blood, Adult, Humans, Male, Aged, Female, Middle Aged, Tumor Markers, Biological blood, Prognosis, Disease-Free Survival, Neoplasm Metastasis, Carcinoma, Non-Small-Cell Lung blood, Glycoproteins blood, Lectins blood",
author = "Ina Thoem and Birte Andritzky and Gunter Schuch and Iris Burkholder and Lutz Edler and Johansen, {Julia S} and Carsten Bokemeyer and Udo Schumacher and Heinz-Eckart Laack",
year = "2010",
language = "Deutsch",
volume = "116",
pages = "4114--4121",
journal = "CANCER-AM CANCER SOC",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "17",

}

RIS

TY - JOUR

T1 - Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer.

AU - Thoem, Ina

AU - Andritzky, Birte

AU - Schuch, Gunter

AU - Burkholder, Iris

AU - Edler, Lutz

AU - Johansen, Julia S

AU - Bokemeyer, Carsten

AU - Schumacher, Udo

AU - Laack, Heinz-Eckart

PY - 2010

Y1 - 2010

N2 - The glycoprotein YKL-40 is synthesized both by cancer cells and by tumor-associated macrophages and plays a functional role in tumor progression. Consequently, high serum YKL-40 levels have been associated with a poor prognosis in patients with several cancer types. However, the role of YKL-40 has not been established in nonsmall cell lung cancer (NSCLC).

AB - The glycoprotein YKL-40 is synthesized both by cancer cells and by tumor-associated macrophages and plays a functional role in tumor progression. Consequently, high serum YKL-40 levels have been associated with a poor prognosis in patients with several cancer types. However, the role of YKL-40 has not been established in nonsmall cell lung cancer (NSCLC).

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Tumor Markers, Biological blood

KW - Prognosis

KW - Disease-Free Survival

KW - Neoplasm Metastasis

KW - Carcinoma, Non-Small-Cell Lung blood

KW - Glycoproteins blood

KW - Lectins blood

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Tumor Markers, Biological blood

KW - Prognosis

KW - Disease-Free Survival

KW - Neoplasm Metastasis

KW - Carcinoma, Non-Small-Cell Lung blood

KW - Glycoproteins blood

KW - Lectins blood

M3 - SCORING: Zeitschriftenaufsatz

VL - 116

SP - 4114

EP - 4121

JO - CANCER-AM CANCER SOC

JF - CANCER-AM CANCER SOC

SN - 0008-543X

IS - 17

M1 - 17

ER -